Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Alliance for Clinical Trials in Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2011-01-01

Employees: 251

Market Cap: -

Website: https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Phase 3

Not yet recruiting

Conditions: Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Vaginal Atrophy
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8

First Posted Date: 2022-05-18

Last Posted Date: 2024-05-23

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 250

Registration Number: NCT05379153

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Ann Arbor Stage I Lymphoma
Ann Arbor Stage II Lymphoma
Ann Arbor Stage III Lymphoma
Ann Arbor Stage IV Lymphoma
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Gastroesophageal Junction Adenocarcinoma
Head and Neck Carcinoma

First Posted Date: 2022-04-19

Last Posted Date: 2025-03-30

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 2000

Registration Number: NCT05334069

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 690 locations

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Phase 2

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Dexamethasone
Biological: Inotuzumab Ozogamicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Methylprednisolone
Biological: Rituximab
Drug: Prednisone
Drug: Mercaptopurine
Drug: Doxorubicin

First Posted Date: 2022-03-31

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 68

Registration Number: NCT05303792

Locations: 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States

and more 69 locations

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2

Active, not recruiting

Conditions: Unresectable Pancreatic Neuroendocrine Carcinoma
Metastatic Pancreatic Neuroendocrine Tumor

Interventions: Drug: Capecitabine
Drug: Lutetium Lu 177 Dotatate
Other: Quality-of-Life Assessment
Drug: Temozolomide
Other: Questionnaire Administration

First Posted Date: 2022-02-21

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 31

Registration Number: NCT05247905

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States

and more 168 locations

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Phase 2

Active, not recruiting

Conditions: Castration-Sensitive Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer AJCC V8
Stage IVA Prostate Cancer AJCC V8
Stage IVB Prostate Cancer AJCC V8

First Posted Date: 2022-02-16

Last Posted Date: 2025-01-15

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 79

Registration Number: NCT05241860

Locations: 🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
Mercy Hospital Fort Smith, Ft. Smith, Arkansas, United States
🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States

and more 323 locations

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Phase 3

Recruiting

Conditions: Cigarette Smoking-Related Carcinoma

First Posted Date: 2021-08-17

Last Posted Date: 2025-06-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 600

Registration Number: NCT05008848

Locations: 🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
🇺🇸
Saint Helena Hospital, Saint Helena, California, United States

and more 193 locations

Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

Phase 3

Active, not recruiting

Conditions: Breast Carcinoma
Mastectomy Patient

First Posted Date: 2021-08-04

Last Posted Date: 2025-04-29

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 216

Registration Number: NCT04989504

Locations: 🇺🇸
Fremont - Rideout Cancer Center, Marysville, California, United States
🇺🇸
Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States
🇺🇸
Beebe South Coastal Health Campus, Frankford, Delaware, United States

and more 46 locations

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Phase 3

Recruiting

Conditions: Anorexia
Hematopoietic and Lymphoid Cell Neoplasm
Advanced Malignant Solid Neoplasm

Interventions: Drug: Olanzapine
Drug: Megestrol Acetate
Other: Questionnaire Administration

First Posted Date: 2021-06-25

Last Posted Date: 2025-06-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 360

Registration Number: NCT04939090

Locations: 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States

and more 281 locations

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2

Recruiting

Conditions: Angioimmunoblastic T-cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Follicular T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Etoposide
Drug: Duvelisib
Drug: Oral azacitidine

First Posted Date: 2021-03-17

Last Posted Date: 2025-06-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 170

Registration Number: NCT04803201

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 83 locations

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

Phase 3

Active, not recruiting

Conditions: BRCA1 Mutation
Breast Cancer
Breast Diseases
Breast Neoplasms
Breast Carcinoma
Neoplasms

Interventions: Drug: Placebo
Drug: Denosumab
Other: Quality-of-Life Assessment

First Posted Date: 2021-01-15

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 300

Registration Number: NCT04711109

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States

and more 44 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy